Tracing Tumor and T Cell Metabolism in Ovarian Cancer Patients
Metabolic Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients
This study is testing how the metabolism of tumor and immune cells in the fluid around ovarian cancer tumors changes when patients receive a special glucose infusion.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | British Columbia Cancer Agency Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Victoria, British Columbia) |
| Trial ID | NCT05025878 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the metabolism of cells within the ascites tumor microenvironment of ovarian cancer patients. Up to 10 eligible participants will receive an intravenous infusion of labeled glucose during a standard paracentesis procedure. Continuous glucose monitoring will be employed, and ascites samples will be collected for analysis using flow cytometry and mass spectrometry to assess metabolic states and metabolite profiles. The study is conducted at BC Cancer - Victoria and involves collaboration with several prominent research institutions.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with ovarian cancer and ascites requiring drainage.
Not a fit: Patients with diabetes or those undergoing chemotherapy during the study period may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of tumor metabolism in ovarian cancer, potentially leading to improved treatment strategies.
How similar studies have performed: While this approach is innovative, similar studies investigating tumor metabolism have shown promise, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ovarian cancer * Any stage or grade of disease * Ascites fluid that requires draining * Any treatment regimen * Primary or recurrent ascites * Understands the concept of the study and give informed consent. Exclusion Criteria: * Participants must not have diabetes or abnormal hemoglobin A1C levels. * The patient's glucose levels must be between 4 - 11.1 mM before administering an infusion. This is to ensure that patients are within normal blood glucose levels, as described by Diabetes Canada. * Participants cannot receive chemotherapy treatment during the 5 hour duration of the experiment as it may compromise the integrity of the data.
Where this trial is running
Victoria, British Columbia
- Jennifer Rauw — Victoria, British Columbia, Canada (Recruiting)
Study contacts
- Study coordinator: Julian J. Lum, PhD
- Email: JLum@bccancer.bc.ca
- Phone: 250-519-5700
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.